Search

Your search keyword '"Arsang‐Jang, Shahram"' showing total 514 results
Start Over Author "Arsang‐Jang, Shahram"
514 results on '"Arsang‐Jang, Shahram"'

5. Empagliflozin improves high-sensitive cardiac troponin-I and high-density lipoprotein cholesterol in patients with type 2 diabetes mellitus and coronary artery disease: a post-hoc analysis of EMPA-CARD Trial

Author

Taheri, Homa, Chiti, Hossein, Reshadmanesh, Tara, Gohari, Sepehr, Jalilvand, Ahmad, Arsang-Jang, Shahram, Ismail-Beigi, Faramarz, Ghanbari, Samin, Dadashi, Mohsen, Asgari, Atieh, Mahjani, Mahsa, Karbalaee‑Hasani, Amir, and Ahangar, Hassan

Published
2023
Full Text
View/download PDF

7. Safety and Outcomes of Intravenous Thrombolytic Therapy in Ischemic Stroke Patients with COVID-19: CASCADE Initiative

Author

Sasanejad, Payam, Afshar Hezarkhani, Leila, Arsang-Jang, Shahram, Tsivgoulis, Georgios, Ghoreishi, Abdoreza, Barlinn, Kristian, Rahmig, Jan, Farhoudi, Mehdi, Sadeghi Hokmabadi, Elyar, Borhani-Haghighi, Afshin, Sariaslani, Payam, Sharifi-Razavi, Athena, Ghandehari, Kavian, Khosravi, Alireza, Smith, Craig, Nilanont, Yongchai, Akbari, Yama, Nguyen, Thanh N, Bersano, Anna, Yassi, Nawaf, Yoshimoto, Takeshi, Lattanzi, Simona, Gupta, Animesh, Zand, Ramin, Rafie, Shahram, Pourandokht Mousavian, Seyede, Reza Shahsavaripour, Mohammad, Amini, Shahram, Kamenova, Saltanat U, Kondybayeva, Aida, Zhanuzakov, Murat, Macri, Elizabeth M, Nobleza, Christa O'Hana S, Ruland, Sean, Cervantes-Arslanian, Anna M, Desai, Masoom J, Ranta, Annemarei, Moghadam Ahmadi, Amir, Rostamihosseinkhani, Mahtab, Foroughi, Razieh, Hooshmandi, Etrat, Akhoundi, Fahimeh H, Shuaib, Ashfaq, Liebeskind, David S, Siegler, James, Romano, Jose G, Mayer, Stephan A, Bavarsad Shahripour, Reza, Zamani, Babak, Woolsey, Amadene, Fazli, Yasaman, Mojtaba, Khazaei, Isaac, Christian F, Biller, Jose, Di Napoli, Mario, and Azarpazhooh, M Reza

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Neurosciences, Stroke, Brain Disorders, Clinical Research, Good Health and Well Being, Aged, Aged, 80 and over, COVID-19, Disability Evaluation, Europe, Female, Fibrinolytic Agents, Hospital Mortality, Humans, Infusions, Intravenous, Intracranial Hemorrhages, Iran, Ischemic Stroke, Male, Middle Aged, Risk Assessment, Risk Factors, Thrombolytic Therapy, Time Factors, Treatment Outcome, COVID 19, Thrombolytic therapy, Longitudinal study, Safety, Outcomes, Disability, Stroke severity, death, Neurology & Neurosurgery, Clinical sciences
Abstract

BackgroundThere is little information regarding the safety of intravenous tissue plasminogen activator (IV-tPA) in patients with stroke and COVID-19.MethodsThis multicenter study included consecutive stroke patients with and without COVID-19 treated with IV-tPA between February 18, 2019, to December 31, 2020, at 9 centers participating in the CASCADE initiative. Clinical outcomes included modified Rankin Scale (mRS) at hospital discharge, in-hospital mortality, the rate of hemorrhagic transformation. Using Bayesian multiple regression and after adjusting for variables with significant value in univariable analysis, we reported the posterior adjusted odds ratio (OR, with 95% Credible Intervals [CrI]) of the main outcomes.ResultsA total of 545 stroke patients, including 101 patients with COVID-19 were evaluated. Patients with COVID-19 had a more severe stroke at admission. In the study cohort, 85 (15.9%) patients had a hemorrhagic transformation, and 72 (13.1%) died in the hospital. After adjustment for confounding variables, discharge mRS score ≥2 (OR: 0.73, 95% CrI: 0.16, 3.05), in-hospital mortality (OR: 2.06, 95% CrI: 0.76, 5.53), and hemorrhagic transformation (OR: 1.514, 95% CrI: 0.66, 3.31) were similar in COVID-19 and non COVID-19 patients. High-sensitivity C reactive protein level was a predictor of hemorrhagic transformation in all cases (OR:1.01, 95%CI: 1.0026, 1.018), including those with COVID-19 (OR:1.024, 95%CI:1.002, 1.054).ConclusionIV-tPA treatment in patients with acute ischemic stroke and COVID-19 was not associated with an increased risk of disability, mortality, and hemorrhagic transformation compared to those without COVID-19. IV-tPA should continue to be considered as the standard of care in patients with hyper acute stroke and COVID-19.

Published
2021

8. ACURATE neo2 Transcatheter aortic valve implantation without balloon aortic valvuloplasty - direct ACURATE neo2

Author

Elkoumy, Ahmed, Rück, Andreas, Abdel-Wahab, Mohamed, Thiele, Holger, Rudolph, Tanja K., Wolf, Alexander, Wambach, Jan Martin, De Backer, Ole, Sondergaard, Lars, Hengstenberg, Christian, Abdelshafy, Mahmoud, Arsang-Jang, Shahram, Elzomor, Hesham, Laine, Mika, Bjursten, Henrik, Götberg, Matthias, Wykrzykowska, Joanna J., Mohamed, Sameh K., Pellegrini, Costanza, Rheude, Tobias, Toggweiler, Stefan, Saleh, Nawzad, Meduri, Christopher U., Kim, Won-Keun, and Soliman, Osama

Published
2024
Full Text
View/download PDF

9. Stroke Care Trends During COVID-19 Pandemic in Zanjan Province, Iran. From the CASCADE Initiative: Statistical Analysis Plan and Preliminary Results

Author

Ghoreishi, Abdoreza, Arsang-Jang, Shahram, Sabaa-Ayoun, Ziad, Yassi, Nawaf, Sylaja, PN, Akbari, Yama, Divani, Afshin A, Biller, Jose, Phan, Thanh, Steinwender, Sandy, Silver, Brian, Zand, Ramin, Bin Basri, Hamidon, Iqbal, Omer M, Ranta, Annemarei, Ruland, Sean, Macri, Elizabeth, Ma, Henry, Nguyen, Thanh N, Abootalebi, Shahram, Gupta, Animesh, Alet, Matias, Lattanzi, Simona, Desai, Masoom, Gagliardi, Rubens J, Girotra, Tarun, Inoue, Manabu, Yoshimoto, Takeshi, Isaac, Cristian Flavo, Mayer, Stephan A, Morovatdar, Negar, Nilanont, Yongchai, Nobleza, Christa O'Hana S, Saber, Hamidreza, Kamenova, Saltanat, Kondybayeva, Aida, Krupinski, Jerzy, Siegler, James E, Stranges, Saverio, Torbey, Michel T, Yorio, Diana, Zurrú, María Cristina, Rubinos, Clio Aracelli, Shahripour, Reza Bavarsad, Borhani-Haghighi, Afshin, Di Napoli, Mario, and Azarpazhooh, M Reza

Subjects
Stroke, Brain Disorders, Neurosciences, Patient Safety, Health and social care services research, 8.1 Organisation and delivery of services, Good Health and Well Being, Aged, Aged, 80 and over, Bayes Theorem, Brain Ischemia, COVID-19, Female, Hospital Mortality, Hospitalization, Humans, Interrupted Time Series Analysis, Intracranial Hemorrhages, Iran, Length of Stay, Male, Middle Aged, Outcome and Process Assessment, Health Care, Recovery of Function, Thrombolytic Therapy, Time Factors, Time-to-Treatment, Treatment Outcome, Epidemiology, Outcome, Mortality, Disability, Stroke care, Clinical Sciences, Neurology & Neurosurgery, Clinical sciences
Abstract

BackgroundThe emergence of the COVID-19 pandemic has significantly impacted global healthcare systems and this may affect stroke care and outcomes. This study examines the changes in stroke epidemiology and care during the COVID-19 pandemic in Zanjan Province, Iran.MethodsThis study is part of the CASCADE international initiative. From February 18, 2019, to July 18, 2020, we followed ischemic and hemorrhagic stroke hospitalization rates and outcomes in Valiasr Hospital, Zanjan, Iran. We used a Bayesian hierarchical model and an interrupted time series analysis (ITS) to identify changes in stroke hospitalization rate, baseline stroke severity [measured by the National Institutes of Health Stroke Scale (NIHSS)], disability [measured by the modified Rankin Scale (mRS)], presentation time (last seen normal to hospital presentation), thrombolytic therapy rate, median door-to-needle time, length of hospital stay, and in-hospital mortality. We compared in-hospital mortality between study periods using Cox-regression model.ResultsDuring the study period, 1,026 stroke patients were hospitalized. Stroke hospitalization rates per 100,000 population decreased from 68.09 before the pandemic to 44.50 during the pandemic, with a significant decline in both Bayesian [Beta: -1.034; Standard Error (SE): 0.22, 95% CrI: -1.48, -0.59] and ITS analysis (estimate: -1.03, SE = 0.24, p

Published
2020

10. Angiographic quantification of aortic regurgitation following myval octacor implantation; independent core lab adjudication

Author

Elkoumy, Ahmed, Jose, John, Gunasekaran, Sengottuvelu, Kumar, Asish, Srinivas, B.C., Manjunath, C.N., Ravindranath, K.S., Parekh, Maulik, Chandra, Praveen, Kapoor, Rajneesh, Abdelshafy, Mahmoud, Seth, Ashok, Agrawal, Praveer, Mathur, Atul, Rao, Ravindra Singh, Elzomor, Hesham, Sadanada, K.S., Kumar, Vijay, Arsang-Jang, Shahram, Mehrotra, Sanjay, Raghuraman, Bagirath, Khanolkar, Uday, Premchand, Rajendra Kumar, Chopra, Manik, Krishna, Prem, Mehta, Haresh, Gupta, Rahul, Kumar, Viveka, Senguttuvan, Nagendra Boopathy, Baumbach, Andreas, Serruys, Patrick W., and Soliman, Osama

Published
2023
Full Text
View/download PDF

12. The Hospitalization Rate of Cerebral Venous Sinus Thrombosis before and during COVID-19 Pandemic Era: A Single-Center Retrospective Cohort Study

Author

Vasaghi Gharamaleki, Maryam, Habibagahi, Maryam, Hooshmandi, Etrat, Tabrizi, Reza, Arsang-Jang, Shahram, Barzegar, Zohreh, Fadakar, Nima, Reza Ostovan, Vahid, Rahimi-Jaberi, Abbas, Ashjazadeh, Nahid, Petramfar, Peyman, Poursadeghfard, Maryam, Izadi, Sadegh, Nazeri, Masoumeh, Bazrafshan, Hanieh, Bahrami, Zahra, Karimlu, Sedigheh, Shaghayegh Zafarmand, Seyedeh, Bayat, Mahnaz, Saied Salehi, Mohammad, Owjfard, Maryam, Karimi-Haghighi, Saeideh, Safari, Anahid, Shakibajahromi, Banafsheh, Lim Alvin Chew, Beng, Worral, Bradford B. g, Coutinho, Jonathan M., Garcia-Esperon, Carlos, Spratt, Neil, Levi, Christopher, Azarpazhooh, Mahmoud Reza, and Borhani-Haghighi, Afshin

Published
2022
Full Text
View/download PDF

15. The effect of EMPAgliflozin on markers of inflammation in patients with concomitant type 2 diabetes mellitus and Coronary ARtery Disease: the EMPA-CARD randomized controlled trial

Author

Gohari, Sepehr, Reshadmanesh, Tara, Khodabandehloo, Hadi, Karbalaee-Hasani, Amir, Ahangar, Hassan, Arsang-Jang, Shahram, Ismail-Beigi, Faramarz, Dadashi, Mohsen, Ghanbari, Samin, Taheri, Homa, Fathi, Mojtaba, Muhammadi, Muhammad Javad, Mahmoodian, Reyhaneh, Asgari, Atieh, Tayaranian, Mohammadreza, Moharrami, Mehdi, Mahjani, Mahsa, Ghobadian, Bijan, Chiti, Hossein, and Gohari, Sheida

Published
2022
Full Text
View/download PDF

28. Characterization of driver mutations identifies gene signatures predictive of prognosis and treatment sensitivity in multiple myeloma.

Author

Li, Jian-Rong, Parthasarathy, Abinand Krishna, Kannappan, Aravind Singaram, Arsang-Jang, Shahram, Dong, Jing, and Cheng, Chao

Subjects
MULTIPLE myeloma, NUCLEAR proteins, RISK assessment, RESEARCH funding, TREATMENT effectiveness, CELLULAR signal transduction, GENES, PROTEASE inhibitors, BORTEZOMIB, GENE expression profiling, GENETIC mutation, SURVIVAL analysis (Biometry), MONOCLONAL gammopathies, PHARMACODYNAMICS
Abstract

In multiple myeloma (MM), while frequent mutations in driver genes are crucial for disease progression, they traditionally offer limited insights into patient prognosis. This study aims to enhance prognostic understanding in MM by analyzing pathway dysregulations in key cancer driver genes, thereby identifying actionable gene signatures. We conducted a detailed quantification of mutations and pathway dysregulations in 10 frequently mutated cancer driver genes in MM to characterize their comprehensive mutational impacts on the whole transcriptome. This was followed by a systematic survival analysis to identify significant gene signatures with enhanced prognostic value. Our systematic analysis highlighted 2 significant signatures, TP53 and LRP1B, which notably outperformed mere mutation status in prognostic predictions. These gene signatures remained prognostically valuable even when accounting for clinical factors, including cytogenetic abnormalities, the International Staging System (ISS), and its revised version (R-ISS). The LRP1B signature effectively distinguished high-risk patients within low/intermediate-risk categories and correlated with significant changes in the tumor immune microenvironment. Additionally, the LRP1B signature showed a strong association with proteasome inhibitor pathways, notably predicting patient responses to bortezomib and the progression from monoclonal gammopathy of unknown significance to MM. Through a rigorous analysis, this study underscores the potential of specific gene signatures in revolutionizing the prognostic landscape of MM, providing novel clinical insights that could influence future translational oncology research. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results